Abstracts Archive - Page 675 of 2607 - ACR Meeting Abstracts

Abstract Number: PP10 • ACR Convergence 2022
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Brooklyn Johnson¹ and Kathleen Collins², ¹Memphis, TN, ²LeBonheur Children's Hospital, Memphis, TN
Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Michael Scepaniak, Cockeysville, MD
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
Abstract Number: 2264 • ACR Convergence 2022
Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Andrea Largent¹, Jane Buckner², David Rawlings¹ and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression…
Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Vibeke Strand¹, Jennifer Sloane Lazar², Michael C Nivens³, Jingdong Chao⁴, Stefano Fiore⁵, Angeliki Giannelou⁶, Lita Araujo⁷ and Jerome Msihid⁸, ¹Stanford University School of Medicine, Stanford, CA, ²Sanofi, Delray Beach, FL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁴Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Hoboken, NJ, ⁷Sanofi, Cambridge, MA, ⁸Sanofi, Chilly-Mazarin, France
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: PP16 • ACR Convergence 2022
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
Ashley Krivohlavek, Oklahoma City, OK
Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
Abstract Number: PP21 • ACR Convergence 2022
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY
Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
Abstract Number: PP20 • ACR Convergence 2022
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
Melissa Allman, Michigan State University, Meridian Charter Township, MI
Background/Purpose: Trauma can have profound detrimental influences on our health and well-being. I am tangibly familiar with how trauma can impact the individual due to…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: PP24 • ACR Convergence 2022
Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp
Kaye Anderson¹, Kristine Carandang² and Courtney Wells³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, ²Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ³University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: PP26 • ACR Convergence 2022
Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life
Catherine Ames¹, Courtney Wells² and Kristine Carandang¹, ¹Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
Abstract Number: PP13 • ACR Convergence 2022
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
Tonya Hinton-Green, Philadelphia, PA
Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…
Abstract Number: PP12 • ACR Convergence 2022
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
Zucy Almonacid¹, Wigna Cruz², Francisca Garcia³, Teresa Hernandez⁴, Velia Martinez⁵, Patricia Mattos³, Mario Mutis⁶ and Denise Serrano⁷, ¹Hicsville, NY, ²Juan Diaz, PR, ³Lake Worth, FL, ⁴Greenacres, FL, ⁵Guaynabo, PR, ⁶Fort Pierce, FL, ⁷Toa Alto, PR
Background/Purpose: Each of us has been diagnosed with rheumatoid arthritis (RA), from as recently as one year ago to as long as 20 years ago.…
Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Georg Pongratz², Luca Navarini³, Rodrigo Garcia Salinas⁴, Tianming Gao⁵, Marie-Claude Laliberté⁶, Ralph Lippe⁷ and Philip J Mease⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, ³Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, ⁴Hospital Italiano de La Plata, La Plata, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Québec, QC, Canada, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].